Nourishing Change: Novo Nordisk to Streamline Operations with 9,000 Job Cuts

Novo Nordisk, the maker of popular weight-loss medications Wegovy and Ozempic, is facing significant challenges. Recently, the company announced it will cut 9,000 jobs, about 11% of its workforce. This move comes after a warning that profits will decline due to the rise of competing weight-loss drugs.

Demand for weight-loss solutions has surged, especially after the pandemic as many people focused on health and wellness. Novo Nordisk’s new CEO, Mike Doustdar, acknowledged the shift in the market. He stated, “Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven.”

Competition is tough, with rivals like Eli Lilly entering the scene with Mounjaro. This drug recently had a price hike in the UK, with costs jumping as much as 170%. Patients reported difficulties obtaining the medication as pharmacies prepared for the price increase, emphasizing the growing tension in the market.

In July, Novo Nordisk warned that its full-year growth wouldn’t meet expectations. The company aims to save around 8 billion Danish kroner (approximately £927 million) by the end of next year. Doustdar, who took over in May 2025, noted the company’s rapid expansion had complicated operations and increased costs.

While many patients benefit from drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro), which act as appetite suppressants, they also come with potential side effects, including nausea and digestive issues. Patient reactions vary widely, with many praising the effectiveness but also expressing frustration over the costs and availability.

The weight-loss market is rapidly evolving. According to a recent report from IBISWorld, the industry has seen a growth rate of 8.5% annually since 2019. As companies adapt to this fast-paced environment, the way patients access these medications—and their affordability—will remain critical.

Novo Nordisk plans to begin discussions with employees about the job cuts and how to move forward. More details are expected during their financial results announcement on November 5.

In this competitive landscape, the focus on innovation and cost management is essential. As Doustdar emphasizes, making tough choices now could ensure the long-term success of Novo Nordisk.



Source link